Study of the modulatory activity of an LHRH [luteinising hormone-releasing hormone] agonist (leuprolide) [leuprorelin] on melanoma peptide vaccines [melanoma vaccine gp100 + melanoma vaccine] as adjuvant therapy in melanoma patients.

Trial Profile

Study of the modulatory activity of an LHRH [luteinising hormone-releasing hormone] agonist (leuprolide) [leuprorelin] on melanoma peptide vaccines [melanoma vaccine gp100 + melanoma vaccine] as adjuvant therapy in melanoma patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2013

At a glance

  • Drugs Leuprorelin (Primary) ; MAGE-A3 peptide vaccine; Melanoma vaccine; Melanoma vaccine gp100
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 May 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top